Stock Ratings / Health Care / HYPD / options

IBIO (23) GANX (41) SER (31) CNTB (26) ⌘ Pro Terminal →

Hyperion DeFi Inc. (HYPD) Options Positioning, Max Pain & Unusual Sweeps

$3.22 -8.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.17

Hyperion DeFi Inc. (HYPD) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $49.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HYPD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Hyperion DeFi Inc. (NASDAQ: HYPD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.22 (-8.13% 1D, market cap $49.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPD ranks #515 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HYPD compare to IBIO and GANX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HYPD carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 62.7%, and ROIC of -35.0%. By comparison, IBIO (iBio Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M) and GANX (Gain Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, HYPD leads on earnings multiple (N/A) while HYPD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HYPD?

▼

Per HYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001682639), Hyperion DeFi Inc. generated $813.5K in revenue (+1318.8% YoY), -$45.3M in net income, and -$14.8M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.17 (-1.65%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HYPD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY HYPD SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 51% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.47-17.6% Next Q

Q2 (-2Q)

Grade D$2.86-0.3% Next Q

Q3 (-1Q)

Grade D$2.85+13% Next Q

Current

Grade D-$3.22-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HYPD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HYPD currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.43) and Max Pain ($3.38) forces dealer call-delta covering toward $7.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HYPD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HYPD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HYPD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HYPD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HYPD)

✓Walkthrough of HYPD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HYPD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.44%📐 HORIZONTAL RANGE

2026-11-03O $3.50H $3.50L $3.22C $3.22VOL 356.4K

RES: $4.24SUP: $2.66SMA50: $3.43SMA200: $3.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HYPD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HYPD Butterfly Map → + Track HYPD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HYPD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HYPD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HYPD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HYPD)

Health Care Rank #515 of 1016 ⚔️ IBIO vs HYPD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HYPD vs. IBIO, GANX, SER, CNTB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Hyperion DeFi Inc. (HYPD) ranks #515 by composite RQD confidence (38/100, grade D-) and #745 by equity capitalization ($49.7M). Within this direct 5-issuer industry benchmark cohort, HYPD leads on earnings valuation at N/A trailing P/E, while HYPD leads on capital efficiency and profitability with -35.0% ROIC and 62.7% gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with HYPD at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HYPD ACTIVE Hyperion DeFi Inc.	D-	38/100	—	62.7%	-35.0%	-8.13%	$49.7M	Benchmark Subject
IBIO iBio Inc.	E	23/100	—	—	-35.0%	-5.52%	$49.4M	/ibio-vs-hypd →
GANX Gain Therapeutics Inc.	D-	41/100	—	—	-35.0%	-5.04%	$49.3M	/ganx-vs-hypd →
SER Serina Therapeutics Inc.	E	31/100	—	—	-35.0%	+2.65%	$49.3M	/ser-vs-hypd →
CNTB Connect Biopharma Holdings Limited	E	26/100	—	—	-35.0%	-3.97%	$50.5M	/cntb-vs-hypd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001682639

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperion DeFi Inc. (HYPD) reported GAAP revenue of $813.5K (+1318.8% vs. FY2024 revenue of $57.3K , and +21380.2% cumulative change since FY2023) , GAAP net income of -$45.3M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+51.2% YoY). On the balance sheet, HYPD closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$813.5K	-$45.3M	-$14.8M	-$14.8M	$51.8M	—
FY2024 (FY)	2024-12-31	$57.3K	-$49.8M	-$30.1M	-$30.3M	$3.7M	—
FY2023 (FY)	2023-12-31	$3.8K	-$27.3M	-$23.8M	-$23.8M	—	—

3. HYPD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HYPD compare to IBIO and GANX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HYPD?

Where is HYPD trading relative to its 50-day, 200-day, and 52-week technical levels?

HYPD last traded at $3.22 (-8.13% on volume of 356,350 shares), positioning the stock -6.12% below its 50-day simple moving average ($3.43) and -4.17% below its 200-day simple moving average ($3.36). Across its 52-week range of $2.34 to $6.87, HYPD sits at the 19.4% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.82 to $3.62).

HYPD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HYPD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for HYPD.

Direct Sub-Reports: HYPD RQD Cockpit HYPD 12M Forecast HYPD Earnings & Move HYPD Dividends & DRIP HYPD Insiders & 13F HYPD Whale Options HYPD Profit Sankey HYPD News & Why

Sector Peer Dials

Gain Therapeutics Inc.

41 /100

SER E

Serina Therapeutics Inc.

31 /100

CNTB E

Connect Biopharma Holdings Limited

HYPD Core Snapshot

Market Cap $49.7M

Trailing / Fwd P/E — / —

Gross Profit Margin 62.7%

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $2.93

FREE TRADER TOOLS

Own HYPD Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With HYPD → 🏆 Trade HYPD in $100K Prop Arena →

HYPD Wire

Why It Moved →

Peer / Ecosystem Wire Cryptonews.net • 18h ago

Hyperion DeFi Buys Back Shares and Retires Legacy Debt

Direct Company Event kalkine.ca • 21h ago

Hyperion DeFi (NASDAQ:HYPD) Penny Stock Climbs 17% Today as Buybacks and Debt Payoff Frame the Move

Peer / Ecosystem Wire Benzinga • 1d ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Peer / Ecosystem Wire Syfe • 1d ago

Marker Therapeutics, Inc. (MRKR) Stock Price & News

Peer / Ecosystem Wire Syfe • 1d ago

RNAZ Stock Price, Quote & News

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HYPD — Hyperion DeFi Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:46:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HYPD scores 50 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows. Fundamental cash engine scores 9 of 20, reflecting ROIC of -35% and an FCF yield of 0%. Whale/13F flow scores 14 of 20, described as institutional accumulation and options positioning. Insider conviction scores 5 of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 11 of 20, reflecting a beta of 1.0 and sector sensitivity. Forensic balance sheet scores 11 of 20, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.5.

For a prospective investor, the weakest pillars are the cash engine and insider conviction, which together signal that the business is not currently generating returns on capital and that insider activity does not provide meaningful confirmation. The strongest pillar relative to its maximum is whale/13F flow, which indicates some institutional interest, though the source data does not quantify the size or direction of those positions. The balance sheet pillar is moderate: the Altman Z-Score and Piotroski F-Score are presented as mid-range readings rather than clear strength. Upside drivers would need to come from a shift in operating performance toward positive returns on capital, which the current data does not show. Valuation tradeoffs are difficult to assess because P/E, EV/EBITDA, and EPS are not available in source data, leaving the market capitalization of $54.1M without an earnings-based reference point. Second-order risk lies in the combination of negative margins and a 0% FCF yield, which constrain the company's ability to self-fund operations.

Open Questions

What is the size and timing of the buyback and legacy debt retirement referenced in the news feed, and how do they change the cash and debt position?
What is the company's product pipeline and revenue model, given that the profile offers no product description?
What drove the -8.26% single-session move and the 17% climb cited in news coverage on the same market?
What are the components of the Altman Z-Score and Piotroski F-Score, and how were the Debt/Equity and balance sheet values derived?
Why are P/E, EPS, and EV/EBITDA absent, and what earnings path does management project?

HYPD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Hyperion DeFi Inc. (HYPD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HYPD Debate Forum (3) ↓

🟡 MARKET WIRE Cryptonews.net • 18h ago

Hyperion DeFi Buys Back Shares and Retires Legacy Debt

Cryptonews.net report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 21h ago

Hyperion DeFi (NASDAQ:HYPD) Penny Stock Climbs 17% Today as Buybacks and Debt Payoff Frame the Move

kalkine.ca report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

Marker Therapeutics, Inc. (MRKR) Stock Price & News

Syfe report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

RNAZ Stock Price, Quote & News

Syfe report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 4d ago

Elon Musk Notes 'Interesting' Hyperliquid Deal After Druckenmiller Endorsement

Elon Musk calls Hyperliquid’s ICE deal “interesting,” extending HYPE’s rally to 17% after Stan Druckenmiller’s public backing.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HYPD Bull vs. Bear Conversation Board — What's Your Call at $3.22?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HYPD 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.48 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HYPD (D • RQD 50/100) a Buy at $3.22?

Welcome to the HYPD (Hyperion DeFi Inc.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.54 (-21.1%)

Spot @ $3.22

Pump the brakes on HYPD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HYPD, but look at what you are paying: current EV/EBITDA multiples with 62.7% gross margins. Unless Hyperion DeFi Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.99 (+23.9%)

Spot @ $3.22

HYPD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HYPD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.22 (52-wk range $2.34 - $6.48), any beat on forward guidance forces shorts and underweight funds to chase.